Telesis Bio Future Growth
Future criteria checks 2/6
Telesis Bio is forecast to grow revenue at 26% per annum. EPS is expected to grow by 53.1% per annum.
Key information
n/a
Earnings growth rate
53.1%
EPS growth rate
| Life Sciences earnings growth | 16.4% |
| Revenue growth rate | 26.0% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 02 Apr 2024 |
Recent future growth updates
Recent updates
The Market Lifts Telesis Bio, Inc. (NASDAQ:TBIO) Shares 38% But It Can Do More
Apr 17
Codex DNA GAAP EPS of -$0.50, revenue of $5.7M; raises FY22 guidance
Aug 09Codex DNA, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 25Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space
Jan 06Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021
Sep 24Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 47 | N/A | N/A | N/A | 1 |
| 12/31/2024 | 36 | N/A | N/A | N/A | 1 |
| 12/31/2023 | 28 | -49 | -37 | -35 | N/A |
| 9/30/2023 | 30 | -39 | -35 | -33 | N/A |
| 6/30/2023 | 31 | -40 | -45 | -42 | N/A |
| 3/31/2023 | 28 | -46 | -49 | -44 | N/A |
| 12/31/2022 | 27 | -48 | -43 | -39 | N/A |
| 9/30/2022 | 21 | -53 | -51 | -46 | N/A |
| 6/30/2022 | 17 | -50 | -48 | -43 | N/A |
| 3/31/2022 | 14 | -45 | -39 | -37 | N/A |
| 12/31/2021 | 11 | -39 | -39 | -37 | N/A |
| 9/30/2021 | 10 | -32 | -29 | -29 | N/A |
| 6/30/2021 | 9 | -27 | -20 | -20 | N/A |
| 3/31/2021 | 8 | -22 | -17 | -17 | N/A |
| 12/31/2020 | 7 | -18 | -16 | -15 | N/A |
| 12/31/2019 | 6 | -10 | -8 | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if TBIO's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if TBIO's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if TBIO's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: TBIO's revenue (26% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: TBIO's revenue (26% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TBIO's Return on Equity is forecast to be high in 3 years time